ونعم، كيليان مورفي مشارك في العمل.نداء إلى جميع عشاق Peaky Blinders، نحن في طريق العودة إلى عالم عائلة شيلبي. فقد حصلت سلسلة مشتقة على الضوء الأخضر رسميًا من Netflix و BBC لموسميْن. الأحداث ستجري في بريطانيا عام 1953، ولم يُعلن بعد عن قرارات متعلقة باختيار طاقم التمثيل، حيث... ونعم، كيليان مورفي مشارك في العمل.نداء إلى جميع عشاق Peaky Blinders، نحن في طريق العودة إلى عالم عائلة شيلبي. فقد حصلت سلسلة مشتقة على الضوء الأخضر رسميًا من Netflix و BBC لموسميْن. الأحداث ستجري في بريطانيا عام 1953، ولم يُعلن بعد عن قرارات متعلقة باختيار طاقم التمثيل، حيث سيتكوّن كل موسم من ست حلقات مدة ...

Laminar is Transforming Manufacturing Lines to Run Faster and More Sustainably with Patented Sensor and Science-Led AI Agents BOSTON, Oct. 2, 2025 /PRNewswire/ -- H2Ok Innovations, the only provider of patented inline sensors powered by science and AI to run faster factories,... Laminar is Transforming Manufacturing Lines to Run Faster and More Sustainably with Patented Sensor and Science-Led AI Agents BOSTON, Oct. 2, 2025 /PRNewswire/ -- H2Ok Innovations, the only provider of patented inline sensors powered by science and AI to run faster factories, today announced its rebrand to Laminar. This new brand aligns with the company's expanding mission to transform manufacturing from reactive, skilled labor-dependent, and inflexible operations to a proactive, autonomous, and agile factory that can meet today's changing consumer patterns and economic environment. Laminar_Sensor H2Ok Innovations was founded with a focus on optimizing CIP and reducing water and chemical usage during cleaning processes. Today, Laminar is expanding its footprint on the production line with a library of purpose-built AI models that combine human expertise with telemetry data to transform an entire factory to run the best version of itself every shift. Laminar's New AI Agent Library for CPG Production Laminar has released a library of purpose-built AI Agents powered by process-specific ML models that deliver closed-loop automation for key CPG manufacturing processes with prescriptive analysis of results, with just a simple prompt to its AI Chat Agent. Capacity and labor-constrained factories can now unlock the true potential of each production line with Laminar's complete solution, which integrates with automation to self-correct processes. The company's offering is a true digital twin of each company and line's manufacturing processes. Unlike alternatives, customers see and implement objective, action-oriented results in days, with near-immediate ROI. Current Laminar AI Agents in production across the globe include: Precise Clean-in-Place Smarter Product Changeovers Faster Line Startups Inline Quality Monitoring of Product and Raw Materials Closed-loop Batch Optimization Filtration in Breweries From Pilot to Closed-Loop Automation in 2 weeks Laminar's patented spectral sensors retrofit seamlessly into existing piping and instrumentation, delivering measurable results from day one. Distinct liquid signatures are created in real-time. These signatures are then instantly analyzed by our purpose-built ML models and converted into precise, actionable inputs for PLCs. The process thus becomes less dependent on experts as they retire and more autonomous, with closed-loop orchestration of production lines. Customers experience faster CIP, smarter changeovers, more consistent product quality from each batch, early detection of any variation from a "golden batch" — all while reducing downtime and cutting down on water, chemical, and energy usage. Manufacturers no longer need to accept the limitations of single-point solutions, standalone sensors, or repetitive consulting projects. Laminar's sensor and AI platform have redefined the standard of running production lines. In the coming months, Laminar will release the next generation of its novel sensor with the ability to sense and develop unique signatures faster and with greater fidelity. Fueling Growth with $12.4M Series A In June, Laminar (as H2Ok Innovations) announced a $12.42M Series A round of funding led by Greycroft, with participation from 2048 Ventures and Construct Capital. The funding accelerates Laminar's ability to bring transformative, instantly deployable technology to scale across manufacturing, supporting faster CIP and changeovers. Headquartered at Greentown Labs in Somerville, MA — North America's leading cleantech incubator. Laminar is a woman-founded startup backed by top-tier investors, including Greycroft, Construct Capital, 2048 Ventures, and Flybridge Capital. Recognized for its innovation and impact, the company was named Unilever's 2023 Startup of the Year supplier and received AB InBev's 2024 Cheers Award for outstanding startup partnership. About Laminar Laminar is a science-led technology company helping the world's leading CPG manufacturers run faster, more sustainable factories. Its proprietary spectral sensing and agentic AI library drive closed-loop automation that reduces downtime, shortens cleaning cycles, and prevents product loss. Laminar delivers measurable ROI by unlocking capacity, conserving water and energy, and driving operational excellence while removing "human-in-the-loop," enabling enterprises to scale and optimize their factories faster. Deployed in factories across six continents and trusted by global leaders like AB InBev, Coca-Cola, and Unilever, Laminar is redefining what it means to unlock your faster factory.Learn more about Laminar at runlaminar.com.

Decline or consent?Hily, a dating app with 39 million worldwide users, just launched a feature to stop unwanted explicit messages and cyberflashing, or sending non-consensual nude images."Consent Guard" uses machine-learning models and custom algorithms to scan for specific... Decline or consent?Hily, a dating app with 39 million worldwide users, just launched a feature to stop unwanted explicit messages and cyberflashing, or sending non-consensual nude images."Consent Guard" uses machine-learning models and custom algorithms to scan for specific words in messages and elements of photos. If something X-rated is ...

NAGOYA, Japan, Oct. 1, 2025 /PRNewswire/ -- The Wenzhou delegation showcased the city's culture and tourism offerings at Tourism EXPO Japan 2025, held from September 25 to 28 at the Aichi International Exhibition Center (Aichi Sky Expo) in Nagoya. NAGOYA, Japan, Oct. 1, 2025 /PRNewswire/ -- The Wenzhou delegation showcased the city's culture and tourism offerings at Tourism EXPO Japan 2025, held from September 25 to 28 at the Aichi International Exhibition Center (Aichi Sky Expo) in Nagoya. Representing the city's unique blend of cultural traditions and natural beauty, the delegation engaged with Japanese travelers through a dynamic presentation of Wenzhou's arts, heritage, and visitor attractions, fostering international exchange and supporting inbound travel to Wenzhou. The initiative culminated in a Wenzhou cultural tourism presentation on September 28 at the expo's central stage. During the event, a presenter guided attendees through a visually engaging introduction to Wenzhou's scenic destinations, including the iconic peaks of Yandang Mountain and the tranquil waters of the Nanxi River, as well as the distinctive Ouyue cultural heritage (the historic cultural identity of the Wenzhou region). The presentation received strong audience response, and a follow-up Q&A session, where five participants received Ou Kiln bell-shaped cups—ceramic works symbolizing Wenzhou's centuries-old craftsmanship—served as a meaningful connection to the city's artistic traditions. The Wenzhou exhibit booth drew steady visitor interest throughout the event. Striking images of Wenzhou's landscapes were paired with carefully curated displays of intangible cultural heritage (ICH), while informational materials provided attendees with in-depth background on the city's tourism offerings. The interactive demonstration area was a major attraction, featuring hands-on activities such as traditional oil-paper umbrella painting, rubbing printmaking, and rice-dough figurine art—each introducing visitors to the creative spirit of Wenzhou's artisans. For many Japanese participants, these interactive sessions offered a memorable and personal introduction to Wenzhou's rich cultural traditions. The exhibition enhanced awareness of Wenzhou among Japanese travelers, many of whom expressed interest in visiting the city to explore its natural and cultural landmarks firsthand. An official with the Wenzhou Municipal Bureau of Culture, Radio, Television and Tourism noted that the delegation's participation strengthened ties between Wenzhou and Japan, adding that the bureau will continue building on this momentum through future cultural and tourism exchanges designed to welcome more visitors from Japan to Wenzhou.

SINGAPORE: CNA won a total of nine awards – five gold and four silver – for its content, website and app at the 2025 w3 Awards.The w3 Awards celebrates excellence in websites, online marketing, web videos, mobile sites and apps, social media, podcasts, and emerging technologies... SINGAPORE: CNA won a total of nine awards – five gold and four silver – for its content, website and app at the 2025 w3 Awards.The w3 Awards celebrates excellence in websites, online marketing, web videos, mobile sites and apps, social media, podcasts, and emerging technologies created by digital content

SEOUL, South Korea, Oct. 2, 2025 /PRNewswire/ -- SurplusGLOBAL, a global leader in legacy semiconductor equipment and parts solutions, announced it will showcase the rapid growth of its www.SemiMarket. SEOUL, South Korea, Oct. 2, 2025 /PRNewswire/ -- SurplusGLOBAL, a global leader in legacy semiconductor equipment and parts solutions, announced it will showcase the rapid growth of its www.SemiMarket.com platform and debut its new intelligent Atomic Layer Deposition (ALD) technology at SEMICON WEST 2025, October 7–9 at the Phoenix Convention Center. SurplusGLOBAL to Showcase SemiMarket Growth and Intelligent ALD Technology at SEMICON WEST 2025 in Phoenix Since its beta launch in June 2025, SemiMarket has surpassed 120,000 listings, is on track for 200,000 by year-end. The company is targeting 500,000 listings in 2026 and 1 million by 2027. The platform's seller base has also expanded rapidly, with registrations growing 175% since June, reflecting global adoption and trust in SemiMarket as the industry's most reliable source for legacy semiconductor parts. Ahead of its Grand Opening this December, SemiMarket is adding AI-driven services such as seller-friendly item recommendations, category suggestions, and customized event alerts to further enhance user experience and engagement. By combining structured cataloging, valuation, and global trading, SemiMarket offers unmatched reliability and transparency for Fabs, OEMs, and buyers worldwide. The company emphasized that information credibility and data integrity remain central to the SemiMarket experience, ensuring customers can source legacy parts with confidence. In addition to platform growth, SurplusGLOBAL will unveil its intelligent ALD solution, developed by retrofitting conventional furnace systems into Plasma-Enhanced ALD (PEALD) tools designed for mass production. The system integrates sub-100ms high-speed sensors and a built-in Fault Detection and Classification (FDC) module, unifying process and measurement data. By applying advanced algorithms for correlation modeling, anomaly detection, and predictive control, the equipment brings next-level intelligence and stability to deposition processes. "SemiMarket's rapid growth demonstrates the global demand for a trusted, transparent, and scalable marketplace for legacy equipment and parts. At the same time, our intelligent ALD solution shows how process innovation and legacy asset utilization can go hand in hand to bring new value to fabs and OEMs worldwide," said Bruce Kim, CEO of SurplusGLOBAL. SurplusGLOBAL will exhibit at booth #1629 throughout SEMICON WEST 2025. With the event debuting in Phoenix, the company aims to demonstrate how a robust global marketplace and next-generation intelligent process tools can address the semiconductor industry's evolving challenges.

ALPHARETTA, Ga., Oct. 2, 2025 /PRNewswire/ -- Arclin, a leading material science company, announced that it has completed the purchase of Polymer Solutions Group ("PSG"), a manufacturer of proprietary and custom polymer additives, dispersions and release agents for the rubber,... ALPHARETTA, Ga., Oct. 2, 2025 /PRNewswire/ -- Arclin, a leading material science company, announced that it has completed the purchase of Polymer Solutions Group ("PSG"), a manufacturer of proprietary and custom polymer additives, dispersions and release agents for the rubber, plastic and engineered wood industries. "We are excited about the addition of PSG and their trusted brands, teams and technologies," said Bradley Bolduc, Arclin's President and CEO. "They complement our current businesses well, specifically in the building, construction and transportation industries," said Bolduc. "Arclin and PSG manufacture complementary chemistries in engineered wood and rubber that will allow us to expand our reach in those markets," said Bolduc. The acquisition of PSG expands Arclin's capabilities in North America and is viewed as a key step in the company's strategy toward expanding its product presence into sectors that are adjacent to its core chemistries and business. Arclin will operate PSG's manufacturing facilities in Cleveland, OH and Albany, GA, as well as a Research & Development facility in Macon, GA. The acquisition will add approximately 200 new team members to Arclin's existing 1,000-person team. "Adding PSG to the Arclin team strengthens our industry-leading fire protection and transportation businesses with new technologies that will serve to expand our product offerings in these sectors," Bolduc continued. "This acquisition will also provide access to additional end markets, continuing Arclin's transformation into a protection-focused material science company serving attractive, high-growth markets and applications." "The sale of PSG to Arclin was a logical next step for the business," said Mike Ivany, PSG CEO. "Arclin's world-class operations model will take our products and growth to the next level, and we'll benefit from their knowledge, breadth of technical expertise and rapid deployment of resources in support of the growth strategy. Arclin is an exciting home for our team, and we look forward to seeing the business thrive going forward," Ivany added. Moelis & Company LLC served as PSG's financial advisor. About Arclin Arclin is a leading materials science company and manufacturer of polymer technologies, engineered products and specialized materials for the construction, agriculture, transportation infrastructure, weather & fire protection, pharmaceutical, nutrition, electronics, design and other industries. Headquartered in Alpharetta, Georgia, Arclin has offices and manufacturing facilities throughout the U.S., Canada, U.K., and manufactures for customers worldwide. For more information, visit www.arclin.com. About PSG PSG is an innovative manufacturer of class-leading proprietary and custom polymer additives, dispersions, and release agents for the rubber, plastic, and engineered wood industries. PSG offers a variety of customer-centric solutions that meet exacting specifications, provide superior performance characteristics, enhance processing efficiency, optimize supply chains, and lower overall costs. Trusted by the world's leading companies in over 50 countries, our unparalleled products and application expertise cannot be matched by any other supplier. For more information, visit www.polymersolutionsgroup.com. For more information, contact Inquiries@Arclin.com

TAIPEI, Oct. 2, 2025 /PRNewswire/ -- Far Eastern New Century Corporation (FENC) is a global leader in eco-friendly polyester materials, dedicated to the innovation and development of sustainable materials. TAIPEI, Oct. 2, 2025 /PRNewswire/ -- Far Eastern New Century Corporation (FENC) is a global leader in eco-friendly polyester materials, dedicated to the innovation and development of sustainable materials. In 2025, FENC achieved a breakthrough in footwear technology, becoming the first in the world to convert rigid post-consumer PET bottles into recycled thermoplastic polyester elastomer (rTPEE). This next-generation material combines outstanding environmental benefits with superior performance, featuring excellent elasticity, cushioning, and rebound, making it an ideal solution for footwear midsoles. It has already been successfully commercialized and supplied to the French outdoor sports brand SALOMON for its signature Solamphibian amphibious shoes. Compared with petroleum-based virgin TPEE, rTPEE reduces carbon emissions by 10–30%, accelerating the footwear industry's transition toward both high-value and sustainable development. The material has received strong market recognition, with multiple leading international sports brands currently in discussions to adopt it, demonstrating significant market potential. Far Eastern New Century pioneers the world's first commercialized footwear midsoles made from waste PET bottles. Leveraging its core polyester expertise, FENC has developed polyester materials in diverse specifications through polymerization and by modifying the material properties to suit the various shoe components, hence addressing the challenge of separating shoe components for recycling. FENC has developed shoe uppers, laces, linings, insoles, shanks and toe cap adhesive made of recycled polyester (rPET), and midsoles from rTPEE which is based on rPET material, advancing the concept of "single-material, fully recyclable" design. In addition, FENC has developed FENC® TopGreen® AirTek PU technology, which utilizes industrially captured CO2 as a raw material to produce high-performance elastic materials. These materials can be widely applied in footwear, stretch fabrics, waterproof-breathable membranes, and synthetic leather. This innovative solution eliminates the use of highly toxic phosgene and isocyanates traditionally found in conventional polyurethane (PU) manufacturing, offering a safer and more environmentally friendly production process. Compared to traditional thermoplastic polyurethane (TPU), AirTek PU achieves up to a 58% reduction in carbon emissions while maintaining both performance and functionality. It represents a breakthrough that combines eco-friendliness, non-toxicity, carbon reduction and high performance. FENC was awarded Second Prize at the Innovation Award "Best CO2 Utilisation 2025", held in Cologne, Germany, becoming the first Asian company to receive the award since its inception, showcasing FENC's leadership in global sustainable material innovation. FENC continues to advance sustainable materials and low-carbon innovation technologies, promoting a circular economy and driving the world toward a net-zero future. About Far Eastern New Century Corporation (FENC) Founded in 1949 as the parent company of the conglomerate Far Eastern Group, FENC is an international company, based in Taiwan, operating in the USA, Japan, Mainland China, Vietnam, Malaysia, Philippines and selling to the name brands around the world. FENC is the world's largest supplier of food-grade rPET, providing customers with comprehensive green product solutions, and is the only polyester supplier in the world vertically integrated to offer a product spectrum spanning from raw materials to consumer end products such as garments. To learn more about FENC please visit https://www.fenc.com/en-US

- Record-high competition ratio of 56:1... Winning dish "Kimpacho" selected after final round among eight contestants - Kimchi recipes from professional chefs to home cooks draw attention SEOUL, South Korea, Oct. - Record-high competition ratio of 56:1... Winning dish "Kimpacho" selected after final round among eight contestants - Kimchi recipes from professional chefs to home cooks draw attention SEOUL, South Korea, Oct. 2, 2025 /PRNewswire/ -- Daesang's kimchi brand 'Jongga', together with the prestigious U.S. culinary school 'Institute of Culinary Education' and SF Globalize, successfully concluded the '2025 Jongga Kimchi Cook Off' in New York. Winners and judges of the “Jongga Kimchi Cook-off” in the United States posed for a commemorative photo on September 30. The Jongga Kimchi Cook Off is a global event held across the U.S., U.K., and France to showcase the appeal and excellence of kimchi worldwide. In the U.S., the competition has been co-hosted with the Institute of Culinary Education since 2020, drawing growing participation each year as contestants present increasingly diverse dishes featuring kimchi. This year, following successful events in France and the U.K., Daesang wrapped up the U.S. competition, further reinforcing Jongga's standing as a leading global kimchi brand. The U.S. round of the Jongga Kimchi Cook Off took place on the 30th (local time) at New York campus of the Institute of Culinary Education. This year's contest featured the highest-ever competition rate of 56:1, with eight finalists selected to compete. Participants came from a wide range of backgrounds, including professional chefs, accountants, architects, and medical students, highlighting the strong interest in kimchi across the U.S. In particular, Steven Gao, a culinary influencer with 870,000 followers, joined as a special guest and presented recipes using Jongga's U.S.-exclusive Sanhowon Kimchi and Cucumber(Oi) Kimchi, drawing significant attention. The judging panel included Richard La Marita, Lead Chef-Instructor of Culinary Arts at ICE, and Samantha Landwehr, Chef-Instructor at ICE, with guest judge Chef Sungchul Shim, who runs a fine dining Korean restaurant in New York. The judges evaluated each dish based on creativity, artistry, and harmony with kimchi, supported by their deep expertise in Korean cuisine. The grand prize went to chef Zofia Gallick from Brooklyn for her dish "Kimpacho," a chilled soup made with Jongga Kimchi Sliced, tomato, cucumber, and jalapeño. The judges praised the dish for its vibrant flavors and textures. Second place went to Daniel Bologna for "Crispy Kimchi Jam Patty Melt," third place to Onyinyechi Attah for "Kimchi Juice Ayo," and the special Jongga Award was presented to Min Kyu Kim for "Cheung Fun Ssam." Lead Chef-Instructor Richard La Marita commented, "The level of entries this year was remarkably high. Many dishes showed a deep understanding of kimchi's fermentation and used it in highly creative ways." Guest judge Chef Sungchul Shim added, "I never expected to see such variety and sophistication in kimchi-based dishes here in the U.S. It was clear that kimchi is being embraced and integrated into local food culture as a new culinary genre." Oh Yeon-taek, Head of Daesang's Kimchi CIC, stated, "The tremendous interest in this year's competition reaffirmed that kimchi is becoming a familiar part of everyday life for American consumers. We will continue to promote Korean food globally through Jongga and O'food, ensuring people around the world can enjoy and connect with it." Currently, Jongga products are distributed in more than 80 countries worldwide, with the U.S. rising to the No.1 export market for Jongga kimchi since 2023. To meet rapidly growing demand, Jongga established a large-scale kimchi factory in Los Angeles in 2022, the first of its kind by a Korean food company, and has since been producing a variety of products tailored to local food culture. As the world's No.1 packaged kimchi brand, Jongga is also actively expanding consumer touchpoints by hosting cooking competitions, participating in music festivals, and running food truck campaigns to showcase the excellence and versatility of kimchi to global audiences. About Daesang Corporation Founded in 1956, Daesang Corporation has been one of the world's largest producers of fermented food products for over 60 years, and has grown to be the global leading Korean based food company by operating global brands such as Jongga, and O'Food which provides sauce, ready-to-eat meals, and many more products. Headquartered in South Korea, the company has also manufacturing subsidiaries in United States, Poland, China, Indonesia, and Vietnam. Visit www.daesang.com/en for more information.

CODIT issue paper assesses impact of U.S. 50% tariffs on Korea's non-ferrous metals sector, revealing structural vulnerabilities Examines global responses and outlines five policy recommendations for Korea SEOUL, South Korea, Oct. CODIT issue paper assesses impact of U.S. 50% tariffs on Korea's non-ferrous metals sector, revealing structural vulnerabilities Examines global responses and outlines five policy recommendations for Korea SEOUL, South Korea, Oct. 2, 2025 /PRNewswire/ -- The CODIT Global Evidence-Based Policy Institute (Executive Director Hae-young Song), the research arm of AI-powered policy platform CODIT, today released an issue paper titled "U.S. Imposes 50% Tariffs on Aluminum and Copper: Strategic Responses for Korea." The paper analyzes the impact of the Trump administration's new tariffs on Korea's non-ferrous metals sector, examines responses from other major economies, and sets out concrete policy recommendations. CODIT Policy Institute Releases Issue Paper on U.S. 50% Tariffs on Aluminum and Copper, Urges Korea’s Strategic Response Korea's non-ferrous metals industry, valued at KRW 57 trillion, remains structurally vulnerable as it is dominated by small and mid-sized firms. Unlike steel, economies of scale are difficult to achieve, and companies face constraints in R&D, ESG compliance, and supply chain management. The industry's reliance on imported raw materials for aluminum and export-heavy dependence for copper makes it particularly exposed to the new tariffs. According to the paper, the 50% tariffs will sharply cut exports of aluminum sheet, foil, and extrusions, while copper tubes and bars may become virtually unsellable. Korean producers are thus facing a "triple burden": collapsing U.S. exports, rising costs from market diversification, and intensifying pressure to localize production. Beyond direct trade losses, the tariffs are also driving supply chain realignments and forcing companies to reconsider global investment strategies—posing ripple risks for key downstream sectors such as automobiles, semiconductors, and EV batteries. Drawing on responses by Canada, China, Australia, and India—including retaliatory tariffs, WTO action, fiscal support, and diversification measures—the Institute proposes five policy recommendations for Korea: Secure tariff reductions and exemptions through U.S. negotiations. Strengthen bargaining power via bilateral and multilateral alliances. Provide domestic relief to minimize industry damage. Enhance long-term competitiveness through supply chain and data management. Ensure institutional support from the National Assembly. "The 50% tariffs on aluminum and copper pose a serious threat to Korea's strategic industries, yet they have drawn far less attention than steel," the Institute stressed. "Korea must adopt a dual-track approach: negotiating aluminum-specific concessions with the U.S. while simultaneously reinforcing supply chain resilience through long-term policy tools." The CODIT Global Evidence-Based Policy Institute regularly publishes issue papers on trade, ESG, AI, healthcare and pharmaceuticals, and the circular economy, and hosts policy seminars with senior experts from the National Assembly, government agencies, and research institutes to support corporate responses to regulatory change.

Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform that integrates the wisdom of traditional medicine with state-of-the-art technologies. Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform that integrates the wisdom of traditional medicine with state-of-the-art technologies. Patented Flagship NB-A002 is a First-in-class DNA Damage Response ("DDR") therapeutic product candidate, targeting the previously undruggable target ILF2, inducing synthetic lethality in DDR and Homologous Recombination Deficiency Cancers. Patented Drug-Target Interaction Graph Neural Network ("DTIGN") is a Structure-and-Outcome-guided discovery AI Model, designed to enable faster identification of promising drug candidates and significantly reduce R&D costs. Pioneering collaboration with the Nanyang Technological University Singapore ("NTU"). The NYB-NTU joint laboratory aims to revolutionize drug discovery through the power of AI and the medicinal properties of natural compounds. NYB holds a growing portfolio of patents across its drug-candidate pipeline and proprietary nutraceuticals. SINGAPORE, Oct. 2, 2025 /PRNewswire/ -- On October 2nd, 2025, NYB announced that it entered into a business combination agreement ("BCA") with RF Acquisition Corp II ("RFAI") (NASDAQ: RFAI), a publicly traded special purpose acquisition company, in a transaction aimed at making NYB become a publicly listed company (the "Proposed Transaction"). Following the closing, the combined company (the "Combined Company") is expected to be listed on Nasdaq under the reserved ticker symbol "NYB." The Combined Company will continue to be led by serial entrepreneur Roland Ong, Chairman of NYB and Professor Li Hoi Yeung, Lead Principal Investigator of the joint laboratory, along with other key members of the executive leadership team. Mr. Ong and Professor Li co-founded the joint laboratory initiative between NTU and NYB five years ago, receiving funding support from key investors The9 Limited (Nasdaq: NCTY) ("The9"), Mercatus Capital, a Singapore-based family office, and other shareholders. NYB's shareholders, including The9 and Mercatus Capital will retain a majority of the Combined Company's outstanding shares, and NYB will designate a majority of the director nominees for the Combined Company's board. NYB operates an industry-recognized AI Drug Discovery Platform powered by Nvidia, HP, and Equinix NYB is an AI-driven drug discovery and biotechnology company. Its flagship VecuraTM AI platform, powered by the proprietary DTIGN, translates vast biochemical spaces into feasible drug candidates. In 2024, the DTIGN engine outperformed competitors by 27% in benchmarking tests[1], as published in the prestigious IEEE magazine, a peer-reviewed journal. The DTIGN engine was also awarded 1st Prize at the SuperAI Genesis Startup Competition 2025 among over 700 global startups[2], underscoring NYB's pioneering role in AI-biotech innovation. Building on this foundation, and in strategic collaboration with global technology leaders such as NVIDIA, Hewlett Packard Enterprise (HPE), Equinix, and top-tier research institutions, NYB is developing what we believe to be one of the world's largest AI-curated natural compound libraries anchored in Singapore. With this fully integrated ecosystem and go-to-market strategy, we believe NYB is redefining AI-driven drug discovery, accelerating the path to next-generation pharmaceuticals, functional foods, and personalized healthcare solutions. Powered by VecuraTM AI and DTIGN, NYB's AI-guided drug discovery has identified multiple nature-inspired small molecules — such as NB-B101 (solid tumors), NB-C201 (cardiovascular health) and NB-C301 (mental health) all progressing through preclinical stages. Supported by strong intellectual property, including international patent applications and early-stage provisional patents, the pipeline targets high-unmet needs in oncology, cardiovascular aliments, and mental health. First-in-Class ILF2 Oncology Candidate Positioned to Capture Massive Unmet Global Demand NYB is advancing a strong pipeline rooted in Asia's biodiversity, spanning oncology, cardiovascular aliments and mental health therapeutics. We believe that NYB's leading candidate, NB-A002, is a first-in-class oncology therapy targeting the previously undruggable ILF2 protein. By inducing synthetic lethality in HRD cancers, including BRCA-mutated and BRCAness tumors, we believe NB-A002 offers a superior alternative to PARP inhibitors with potential treatments across ovarian, breast, lung and other solid tumors. The global DDR therapy market is valued at $8.3 billion today and expected to reach $19.5 billion by the mid-2030s[3]. With 91% of pan-cancer cases in Chinese populations carrying actionable DDR/HRD alterations, we believe NB-A002 is uniquely positioned to potentially address massive unmet demand in oncology. NYB-NTU Collaboration Unlocks AI and Natural Compounds for Breakthrough Drug Discovery NYB has established a pioneering joint laboratory with NTU, a global AI powerhouse ranked 2nd worldwide for AI by the U.S. News & World Report 2025[4]. The NYB-NTU collaboration is developing the next-generation AI engine underpinning VecuraTM AI, harnessing the power of AI and the therapeutic potential of natural compounds to accelerate discovery across small molecules, biologics, and other large-molecule modalities. This partnership is designed to advance NYB's pipeline across oncology, cardiovascular, metabolic and mental health disciplines, supporting its vision of extending human longevity. Management Commentary Tse Meng Ng, Chairman and CEO of RF Acquisition, comments, "We are thrilled to partner with Roland, Professor Li, and the NYB team at this pivotal moment in their growth journey. NYB has built a truly differentiated AI-powered drug discovery platform, combining world-class research capabilities with a strong pipeline of therapeutic candidates. We believe NYB is uniquely positioned to transform the future of medicine by addressing areas of high unmet medical need. This transaction reflects our confidence in NYB's ability to create lasting value for patients, shareholders, and the broader healthcare ecosystem. We look forward to supporting the Company as it enters the public markets and executes on its vision of reshaping healthcare through innovation." Roland Ong, Group Chairman of NYB, comments, "We are delighted to announce our business combination with RF Acquisition Corp II, marking an important milestone in NYB's journey. AI-driven drug discovery is breaking through barriers that have long hindered the advancement of medicine, significantly reducing R&D time and costs while opening new opportunities for humanity to pursue longevity. Our proprietary DTIGN platform has mapped vast numbers of natural compounds and identified promising candidates, strengthening the feasibility of a new era of drug development. On top of that, our lead molecule NB-A002 introduces a novel approach to treating solid tumors, and we are honored to have received a clinical trial invitation from the head of oncology at one of the world's top universities. At the same time, our pioneering collaboration with NTU continues to propel us forward, building the next generation of AI engines and expanding discovery into biologics and other modalities. Together, these achievements affirm our vision of reshaping healthcare through innovation." Transaction Overview The Proposed Transaction gives NYB approximately $1.5 billion in pre-transaction equity value. NYB's existing shareholders, including The9 and Mercatus Capital will roll over 100% of the equity and retain a majority of the Combined Company's outstanding shares, while NYB will also designate a majority of the Combined Company's board of directors. Following the Proposed Transaction, NYB aims to accelerate the discovery of more effective drug molecules and identify active ingredients from natural sources for use in both pharmaceuticals and traditional medicine. The transaction has been approved by the Board of Directors of NYB and RFAI, and its closing is expected to be in the first or second quarter of 2026, subject to shareholders' approval and the satisfaction of customary closing conditions. Additional information about the Proposed Transaction, including a copy of the business combination agreement and investor presentation, will be provided in one or more Current Reports on Form 8-K to be filed by RFAI with the Securities and Exchange Commission ("SEC"). Advisors Ortoli Rosenstadt LLP is serving as NYB's US counsel. Winston & Strawn LLP is serving as counsel to RFAI. Insight Law LLC is serving as NYB's Singapore counsel. Maples and Calder (Hong Kong) LLP is serving as NYB's Cayman Islands counsel. EarlyBirdCapital, Inc. is serving as a financial advisor to RFAI. About NYB The Company is an AI-driven drug discovery and biotechnology company accelerating the future of medicine through the convergence of artificial intelligence and natural compounds. Its flagship VecuraTM AI platform, powered by the proprietary Drug-Target Interaction Graph Neural Network (DTIGN), translates vast biochemical spaces into feasible drug candidates. Anchored in Singapore, NYB is building what they believe is one of the world's largest AI-curated natural compound libraries in collaboration with global technology leaders NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix, together with leading research institutions. Its pipeline of five molecules targets high unmet needs in oncology, cardiovascular, and mental health, led by NB-A002, a first-in-class targeted therapy addressing cancers with compromised DNA Damage response (DDR). Learn more at https://www.nanyangbiologics.com/ About RF Acquisition Corp II RFAI is a blank check company incorporated as a Cayman Islands corporation whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While RFAI may pursue an initial business combination target in any business, industry, or geographic location, it intends to focus its search on businesses in Asia within the deep technology sector, including artificial intelligence, quantum computing, and biotechnology. RFAI was incorporated in 2024 and is based in Singapore. Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding projections, estimates, and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the estimated implied enterprise value of the Combined Company, NYB's ability to scale and grow its business, the advantages and expected growth of the Combined Company, the Combined Company's ability to source and retain talent, the cash position of the Combined Company following the closing of the Proposed Transaction, RFAI's and NYB's ability to consummate the Proposed Transaction, and expectations related to the terms and timing of the Proposed Transaction, as applicable. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of RFAI's and NYB's management and are not predictions of actual performance. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although each of RFAI and NYB believes that it has a reasonable basis for each forward-looking statement contained in this press release, each of RFAI and NYB cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there will be risks and uncertainties described in the proxy statement/prospectus included in the Registration Statement relating to the Proposed Transaction, which is expected to be filed by the Combined Company with the SEC and other documents filed by the Combined Company or RFAI from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Neither RFAI nor NYB can assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to complete the Proposed Transaction due to the failure to obtain approval from RFAI's shareholders or satisfy other closing conditions in the BCA, the occurrence of any event that could give rise to the termination of the BCA, the ability to recognize the anticipated benefits of the Proposed Transaction, the amount of redemption requests made by RFAI's public shareholders, costs related to the Proposed Transaction, the risk that the Proposed Transaction disrupts current plans and operations as a result of the announcement and consummation of the Proposed Transaction, the outcome of any potential litigation, government or regulatory proceedings, and other risks and uncertainties, including those to be included under the heading "Risk Factors" in the Registration Statement to be filed by the Combined Company with the SEC and those included under the heading "Risk Factors" in RFAI's Annual Report on Form 10-K filed with the SEC on March 25, 2025, the Quarterly Reports on Form 10-Q filed with the SEC on June 14, 2024, August 14, 2024 October 25, 2024, May 12, 2025, and July 28, 2025, respectively. There may be additional risks that neither RFAI nor NYB presently know or that RFAI and NYB currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of RFAI and NYB as of the date of this press release. Subsequent events and developments may cause those views to change. However, while RFAI and NYB may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of RFAI or NYB as of any date subsequent to the date of this press release. Except as may be required by law, neither RFAI nor NYB undertakes any duty to update these forward-looking statements. Additional Information and Where to Find It In connection with the Proposed Transaction, RFAI and the Company intend to cause a registration statement on Form F-4 to be filed with the SEC, which will include a proxy statement to be distributed to RFAI's shareholders in connection with RFAI's solicitation for proxies for the vote by RFAI's shareholders in connection with the Proposed Transaction and other matters as described in the registration statement, as well as a prospectus relating to the Company's securities to be issued in connection with the Proposed Transaction. RFAI's shareholders and other interested persons are advised to read, once available, the preliminary proxy statement/prospectus and any amendments thereto and, once available, the definitive proxy statement/prospectus, in connection with RFAI's solicitation of proxies for its special meeting of shareholders to be held to approve, among other things, the Proposed Transaction, because these documents will contain important information about RFAI, the Company, and the Proposed Transaction. After the registration statement is filed and declared effective, RFAI will mail a definitive proxy statement and other relevant documents to its shareholders as of the record date to be established for voting on the Proposed Transaction. Shareholders may also obtain a copy of the preliminary and definitive proxy statement/prospectus to be included in the registration statement, once available, as well as other documents filed with the SEC regarding the Proposed Transaction and other documents filed with the SEC, without charge, at the SEC's website located at www.sec.gov. Participants in the Solicitation RFAI, NYB, and their respective directors, executive officers, and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitations of proxies from RFAI's shareholders in connection with the Proposed Transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of RFAI's shareholders in connection with the Proposed Transaction will be set forth in the proxy statement/prospectus included in the Registration Statement to be filed with the SEC in connection with the Proposed Transaction. You can find more information about RFAI's directors and executive officers in RFAI's final prospectus related to its initial public offering dated May 17, 2024. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus when it becomes available. Shareholders, potential investors, and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above. No Offer or Solicitation This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the Proposed Transaction and does not constitute an offer to sell or the solicitation of an offer to buy any securities of RFAI, the Company or the Combined Company, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended. [1] https://ieeexplore.ieee.org/document/10645211 [2] https://www.superai.com/reports/2025-event-report [3] https://www.researchandmarkets.com/reports/6071261/dna-repair-drugs-global-strategic-business?srsltid=AfmBOoo9gQPZ_0nEFC_WBFDhdDYNyWGujGAgQbYbNPiB2w9z2BPtO2BP [4] https://www.usnews.com/education/best-global-universities/artificial-intelligence